Covid-19: Oxford’s vaccine is the new frontrunner, to produce 2 billion doses in september

The University of Oxford’s vaccine trial is expected to present some positive results as it has been shown to be ahead of others. The positive news which was reported by a UK journalist is coming on the COVID-19 vaccine that the University of Oxford is developing with British-Swedish multinational pharmaceutical firm, AstraZeneca Plc. 

This is coming moments after it was revealed that Moderna Inc vaccine had recorded positive results in its first stage of the human trial, being able to produce antibodies in all patients in an early test. 

According to a report from Bloomberg, ITV’s Robert Peston said in a tweet post, ‘’The vaccine is generating the kind of antibody and T-cell (killer cell) response that the researchers would hope to see.’’ 

He also added that details of the result will soon be released in a medical journal, The Lancet. 

The University of Oxford’s vaccine trial is led by Sarah Gilbert, who is profiled this week in Bloomberg Businessweek. The trial shot for the vaccine which is regarded as being months ahead of all other key vaccine candidates is already undergoing a third phase trial in Brazil, which ranks second with most infected cases in the world with 1,884,967 infections. 

The human trials of the Oxford vaccine are expected to be through in September as AstraZeneca has lined up agreements to produce 2 billion doses. 

Kate Bingham, the Chair of UK government’s Vaccine Taskforce, told the parliamentary committee in early July that Gilbert’s team has gone ahead of other vaccine contenders to the point where it will likely finish vaccinating subjects in its big 10,000-person efficacy trial before the other vaccine candidates even start testing on that scale. 

It was earlier reported federal researchers said that the Moderna COVID-19 vaccine produced antibodies to the coronavirus in all the 45 patients that were tested in an initial safety trial, clearing a key milestone. 

The US biotech firm’s breakthrough is one of the most promising development yet in the race to develop a vaccine against the virus that has crippled the global economy. 

These vaccine developments are part of several efforts working on a potential vaccine for COVID-19. The World Health Organization (WHO) had disclosed that over 100 vaccines for COVID-19 are currently under development globally. 

Leave a Reply

Your email address will not be published.